StAmP

A Proof of Principle, Double-Blind, Randomised, Placebo-Controlled, Multi Centre Trial of pravaStatin to Ameliorate Early Onset Pre-eclampsia.

StAmP trial objectives: 

The aim of this trial is to establish whether pravastatin causes a significant reduction of circulating anti-angiogenic factors in women with early-onset pre-eclampsia. To answer this hypothesis, we will ask the following: 

  1. Does pravastain, compared with placebo, inhibit anti-angiogenic factors in women with early-onset pre-eclampsia?
  2. If this principle is established, how best can a substantive trial/ health technology assessment be undertaken to develop guidance for routine use of statins in pre-eclampsia?
  3. Are there any adverse effects to the mother or the baby following gestational exposure to pravastatin?

EudraCT Number: 2009-012968-13

ISRCTN Number: 23410175

Funder: Medical Research Council

Grant Holder: Professor Asif Ahmed, Aston University

Sponsor: University College London

Chief Clinical Investigator: Dr David Williams

Trial Coordinating Centre: Birmingham Clinical Trials Unit, University of Birmingham